Clinical Trials
Closed
Phase
Accrual
29%
Published
SWOG Clinical Trial Number
S1106
A Randomized Phase II Trial of R-HCVAD-MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients </= 65 Years of Age With Previously Untreated Mantle Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
10-01-2011
Closed
06-26-2013
ClinicalTrials.gov Registry Number
NCT01412879
Closed
Phase
Accrual
98%
Published
SWOG Clinical Trial Number
S1014
Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II.
Research Committee(s)
Genitourinary Cancer
Activated
08-09-2011
Closed
08-01-2013
ClinicalTrials.gov Registry Number
NCT01309672
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1011
A Phase III Surgical Trial to Evaluate The Benefit Of A Standard Versus An Extended Pelvic Lymphadenectomy Performed At Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer
Research Committee(s)
Genitourinary Cancer
Activated
08-01-2011
Closed
04-15-2017
ClinicalTrials.gov Registry Number
NCT01224665
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1001
A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
Status Notes
Permanent Closure - Step 1 Registration Effective 6/1/2016 at 11:59 p.m. PST
Step 2 registration was permanently closed to accrual effective 11/30/17.
Step 2 registration was permanently closed to accrual effective 11/30/17.
Research Committee(s)
Lymphoma
Activated
07-18-2011
Closed
06-01-2016
ClinicalTrials.gov Registry Number
NCT01359592
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0931
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.
Research Committee(s)
Genitourinary Cancer
Activated
04-01-2011
Closed
09-15-2016
ClinicalTrials.gov Registry Number
NCT01120249
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0833
Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients with Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged </= 65 Years
Research Committee(s)
Myeloma
Activated
03-15-2011
Closed
05-01-2012
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1007
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-responsive and Her2-Negative Breast Cancer according to Recurrence Score (RS).
Status Notes
4/9/21: S1007 Revision #16 protocol and supporting documents are being distributed to sites to begin the participating site implementation process. S1007 Revision #16 is CIRB approved, however SWOG is awaiting final contract execution with the processing laboratories in order to activate the Circulating Biomarker Assessment for Late Relapse Translational Medicine (CBALR TM) Substudy (Registration Step 3) to enrollment. A forthcoming memorandum will be distributed (anticipated May 2021) to activate the S1007 CBALR TM Substudy (Registration Step 3) and the provision of sample collection kits (as indicated in protocol Section 15.3b).
Step 1 Registration was closed to accrual effective October 1, 2015 and Step 2 Registration was closed to accrual effective October 15, 2015.
Step 1 Registration was closed to accrual effective October 1, 2015 and Step 2 Registration was closed to accrual effective October 15, 2015.
Research Committee(s)
Breast Cancer
Activated
01-15-2011
ClinicalTrials.gov Registry Number
NCT01272037
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S1005
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
01-01-2011
Closed
05-01-2013
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0925
A Randomized Phase II Study of Androgen Deprivation Combined with IMC-A12 Versus Androgen Deprivation Alone for Patients with New Hormone-Sensitive Metastatic Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
12-15-2010
Closed
12-01-2012
ClinicalTrials.gov Registry Number
NCT01120236
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0806
A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Research Committee(s)
Lymphoma
Activated
11-15-2010
Closed
10-01-2013
ClinicalTrials.gov Registry Number
NCT00972478
Closed
Phase
Accrual
45%
Published
SWOG Clinical Trial Number
S0933
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Research Committee(s)
Melanoma
Activated
10-28-2010
Closed
11-15-2011
ClinicalTrials.gov Registry Number
NCT01120275
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0910
A Phase II Study of Epratuzumab in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Precursor B-cell Acute Lymphoblastic Leukemia
Research Committee(s)
Leukemia
Activated
08-15-2010
Closed
07-01-2012
Closed
Phase
Accrual
73%
Published
SWOG Clinical Trial Number
S0941
Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients with Advanced Gallbladder Carcinoma or Cholangiocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
04-15-2010
Closed
09-15-2011
ClinicalTrials.gov Registry Number
NCT01093222
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0800
A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (Peg-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer
Research Committee(s)
Breast Cancer
Activated
04-01-2010
Closed
10-01-2012
Closed
Phase
Accrual
91%
Published
SWOG Clinical Trial Number
S0905
A Phase I / Randomized Phase II Study of Cediranib (NSC #732208) Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma
Status Notes
This study permanently closed to accrual February 15, 2016.
Research Committee(s)
Lung Cancer
Activated
03-15-2010
Closed
02-15-2016
ClinicalTrials.gov Registry Number
NCT01064648
Closed
Phase
Accrual
99%
Published
SWOG Clinical Trial Number
S0904
Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel plus Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Research Committee(s)
Gynecologic Cancer
Activated
03-15-2010
Closed
08-01-2011
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S0916
A Phase II Trial of the Anti-CCR2 Antibody MLN1202 in Patients with Bone Metastases
Research Committee(s)
Early Therapeutics & Rare Cancers
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Lung Cancer
Myeloma
Activated
03-01-2010
Closed
03-15-2011
ClinicalTrials.gov Registry Number
NCT01015560
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0715
Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane Induced Neuropathy
Research Committee(s)
Symptom Management and Survivorship
Breast Cancer
Cancer Survivorship
Molecular Epidemiology
Activated
09-15-2009
Closed
02-01-2011
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0805
Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL)
Research Committee(s)
Leukemia
Activated
09-01-2009
ClinicalTrials.gov Registry Number
NCT00390793
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0919
A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)
Status Notes
Permanently closed effective 9/15/17.
Research Committee(s)
Leukemia
Activated
08-15-2009
Closed
09-15-2017
ClinicalTrials.gov Registry Number
NCT00840177